Clinical Trial Update: TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

View source ↗

Summary

The Netherlands Cancer Institute is conducting a trial (NCT06931769) to optimize neoadjuvant/adjuvant systemic therapy for stage III triple-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Breast Cancer | Status: RECRUITING